JP2024520898A5 - - Google Patents

Info

Publication number
JP2024520898A5
JP2024520898A5 JP2023569779A JP2023569779A JP2024520898A5 JP 2024520898 A5 JP2024520898 A5 JP 2024520898A5 JP 2023569779 A JP2023569779 A JP 2023569779A JP 2023569779 A JP2023569779 A JP 2023569779A JP 2024520898 A5 JP2024520898 A5 JP 2024520898A5
Authority
JP
Japan
Prior art keywords
subject
sbcma
level
therapy
blood sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023569779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/072247 external-priority patent/WO2022241430A1/en
Publication of JP2024520898A publication Critical patent/JP2024520898A/ja
Publication of JP2024520898A5 publication Critical patent/JP2024520898A5/ja
Pending legal-status Critical Current

Links

JP2023569779A 2021-05-11 2022-05-11 再発性及び／又は難治性多発性骨髄腫の治療をモニタリングするための方法及び組成物 Pending JP2024520898A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163187344P 2021-05-11 2021-05-11
US63/187,344 2021-05-11
PCT/US2022/072247 WO2022241430A1 (en) 2021-05-11 2022-05-11 Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma

Publications (2)

Publication Number Publication Date
JP2024520898A JP2024520898A (ja) 2024-05-27
JP2024520898A5 true JP2024520898A5 (cg-RX-API-DMAC7.html) 2025-05-19

Family

ID=82399377

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023569779A Pending JP2024520898A (ja) 2021-05-11 2022-05-11 再発性及び／又は難治性多発性骨髄腫の治療をモニタリングするための方法及び組成物

Country Status (10)

Country Link
US (2) US20220373550A1 (cg-RX-API-DMAC7.html)
EP (1) EP4337962A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520898A (cg-RX-API-DMAC7.html)
KR (1) KR20240005919A (cg-RX-API-DMAC7.html)
CN (1) CN117295949A (cg-RX-API-DMAC7.html)
AU (1) AU2022273326A1 (cg-RX-API-DMAC7.html)
CA (1) CA3219969A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023013412A (cg-RX-API-DMAC7.html)
TW (1) TW202309522A (cg-RX-API-DMAC7.html)
WO (1) WO2022241430A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
WO2024168192A1 (en) * 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
EP4698217A1 (en) * 2023-04-19 2026-02-25 Janssen Biotech, Inc. Methods for treating multiple myeloma

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
US20130101599A1 (en) * 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
AU2015357535B2 (en) * 2014-12-05 2020-05-14 Eureka Therapeutics, Inc. Antibodies targeting G-protein coupled receptor and methods of use
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
WO2017210617A2 (en) * 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN112955748A (zh) * 2018-10-31 2021-06-11 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法
US12077592B2 (en) * 2019-01-18 2024-09-03 Janssen Biotech, Inc. GPRC5D chimeric antigen receptors and cells expressing the same
BR112022008522A2 (pt) * 2019-11-05 2022-07-26 Celgene Corp Usos de receptores de antígeno quimérico anti-bcma

Similar Documents

Publication Publication Date Title
Liu et al. Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen–induced lung cancer and determines the efficacy of immunotherapy
Zhou et al. Hepatic NOD2 promotes hepatocarcinogenesis via a RIP2-mediated proinflammatory response and a novel nuclear autophagy-mediated DNA damage mechanism
Chen et al. Silence of long noncoding RNA NEAT1 exerts suppressive effects on immunity during sepsis by promoting microRNA‐125‐dependent MCEMP1 downregulation
Marks et al. Innate immunity in inflammatory bowel disease: a disease hypothesis
Munari et al. Cytokine BAFF released by Helicobacter pylori–infected macrophages triggers the Th17 response in human chronic gastritis
KR20160044030A (ko) 종양 치료용 항-ｂ7-ｈ1 항체
US11730789B2 (en) Cell penetrating antibodies
Zhou et al. Diverse roles of macrophages in intraocular neovascular diseases: a review
Wang et al. Silencing of SAA1 inhibits palmitate-or high-fat diet induced insulin resistance through suppression of the NF-κB pathway
CN112912403A (zh) 治疗肿瘤的方法
Jarneborn et al. Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice
Xie et al. Regorafenib enhances anti-tumor efficacy of immune checkpoint inhibitor by regulating IFN-γ/NSDHL/SREBP1/TGF-β1 axis in hepatocellular carcinoma
IL275438B1 (en) Biomarkers of methotrexate-induced immune tolerance
CN106573056A (zh) 用于诊断和治疗炎症性肠病的方法和组合物
Moon et al. Interleukin-2 improves insulin sensitivity through hypothalamic sympathetic activation in obese mice
Zhou et al. The present roles and future perspectives of Interleukin-6 in biliary tract cancer
Kadota et al. Perioperative management in myasthenia gravis: republication of a systematic review and a proposal by the guideline committee of the Japanese Association for Chest Surgery 2014
Xiao et al. Streptococcus may aggravate inflammatory damage in chronic nephritis via the chemotaxis of Th22 cells
Wang et al. A bifunctional antibody targeting PD-1 and TGF-β signaling has antitumor activity in combination with radiotherapy and attenuates radiation-induced lung injury
Xu et al. IL-17 imbalance promotes the pyroptosis in immune-mediated liver injury through STAT3-IFI16 axis
Perrichet et al. Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer
Çiçek et al. Evaluation of neutrophil/lymphocyte and platelet/lymphocyte ratios in sudden sensorineural hearing loss and relationship with hyperbaric oxygen therapy
Qiao et al. Decreased expression levels of complement regulator CD55 contribute to the development of bullous pemphigoid
CN113454114B (zh) 治疗癌症的药物组合
Shan et al. Fenofibrate maintains the integrity of the blood–brain barrier during cerebral ischemia–reperfusion injury by inhibiting Egr-1: SHAN ET AL.